Development of Quality of Life Questionnaire for Patients with Parkinson’s Disease Undergoing STN-DBS
暂无分享,去创建一个
K. Iihara | Y. Miyagi | J. Kishimoto | K. Samura | Shintaro Ueda | M. Kawaguchi | M. Watari | Yutaka Tokunaga | Hiroko Eguchi
[1] Yi Bao,et al. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis , 2019, Front. Neurol..
[2] M. Rizzone,et al. Long‐term effect of levodopa‐carbidopa intestinal gel on axial signs in Parkinson’s disease , 2019, Acta neurologica Scandinavica.
[3] S. Marino,et al. Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers , 2018, Journal of Neurology.
[4] H. Reichmann,et al. Medical and surgical management of advanced Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[5] M. Merello,et al. Challenges in PD Patient Management After DBS: A Pragmatic Review , 2018, Movement disorders clinical practice.
[6] E. Pekkonen,et al. Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease , 2017, Brain and behavior.
[7] F. Marrosu,et al. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[8] G. Deuschl,et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.
[9] P. Pollak,et al. Effects of varying subthalamic nucleus stimulation on apraxia of lid opening in Parkinson’s disease , 2012, Journal of Neurology.
[10] E. Racine,et al. A Review of Social and Relational Aspects of Deep Brain Stimulation in Parkinson's Disease Informed by Healthcare Provider Experiences , 2011, Parkinson's disease.
[11] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[12] T. Morioka,et al. Assessment of Contact Location in Subthalamic Stimulation for Parkinson’s Disease by Co-Registration of Computed Tomography Images , 2008, Stereotactic and Functional Neurosurgery.
[13] Pablo Martinez-Martin,et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients , 2007, Movement disorders : official journal of the Movement Disorder Society.
[14] Paolo Barone,et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[15] J. Langston,et al. The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.
[16] A. Benabid,et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.
[17] V Sturm,et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD , 2001, Neurology.
[18] A. Damiano,et al. A review of health-related quality-of-life concepts and measures for Parkinson's disease , 1999, Quality of Life Research.
[19] J. Speelman,et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[20] R. Fitzpatrick,et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease , 1995, Quality of Life Research.
[21] F. Valldeoriola,et al. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. , 2019, Journal of Parkinson's disease.